Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Treasury Shares (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Treasury Shares data on record, last reported at $100.2 million in Q4 2025.

  • For Q4 2025, Treasury Shares rose 1014.45% year-over-year to $100.2 million; the TTM value through Dec 2025 reached $100.2 million, up 1014.45%, while the annual FY2025 figure was $100.2 million, 1014.45% up from the prior year.
  • Treasury Shares reached $3.5 million in Q4 2025 per TGTX's latest filing, up from $2.8 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $12.0 million in Q4 2021 and bottomed at $41309.0 in Q1 2021.
  • Average Treasury Shares over 5 years is $1.0 million, with a median of $41309.0 recorded in 2021.
  • Peak YoY movement for Treasury Shares: changed 0.0% in 2021, then surged 9298.29% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $234000.0 in 2021, then changed by 0.0% to $234000.0 in 2022, then changed by 0.0% to $234000.0 in 2023, then surged by 3743.59% to $9.0 million in 2024, then surged by 1014.45% to $100.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $100.2 million in Q4 2025, $100.2 million in Q3 2025, and $22.0 million in Q2 2025.